An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group

Journal article

Transcatheter aortic valve implantation (TAVI) is an effective and established treatment for symptomatic aortic stenosis. However, there is a lack of consensus concerning the need for peri- and post-procedural anti-thrombotic medication. Contemporary guidelines recommend that anti-thrombotic therapy is balanced against a patient’s bleeding risk following TAVI, but do not fully consider the evolving evidence base. The purpose of the Delphi panel recommendations presented here is to provide a consensus elicited from a panel of experts who regularly prescribe anti-thrombotic therapy post-TAVI. The goal was to address evidence gaps across four key topics: anti-thrombotic therapy (anti-platelet and/or anti-coagulant) in TAVI patients in sinus rhythm; anti-thrombotic therapy in TAVI patients with AF; direct oral anti-coagulants versus vitamin K antagonists; and the need for UK/Ireland specific guidance. This consensus statement aims to inform clinical decision-making by providing a concise, evidence-based summary of best practice for prescribing anti-thrombotic therapies following TAVI and highlights areas where further research is needed

Authors: Zaman, A; Prendergast, B; Hildick-Smith, D; Blackman, D; Anderson, R

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Radcliffe Medical Media
• Journal: Interventional Cardiology: Reviews, Research, Resources
• Volume: 18
• Pages: e13-e13
• Article number: e13
• Publication date: 2023-04-10
• DOI: 10.15420/icr.2022.11
• EISSN: 1756-1485
• ISSN: 1756-1477
• Language: English
• Keywords: Internal medicine; Aortic valve stenosis; Expert opinion; Intensive care medicine; Medicine; Stenosis; Cardiology